Rallybio Corporation (RLYB) 10-Year Financial Performance & Capital Metrics

RLYB • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutRallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.Show more

Revenue $636K
EBITDA -$60M +23.4%
Net Income -$58M +22.5%
EPS (Diluted) -1.33 +27.7%
Gross Margin 100%
EBITDA Margin -9491.35%
Operating Margin -9511.95%
Net Margin -9084.12%
ROE -68.85% -27.2%
ROIC -69.81% -15.0%
Debt/Equity 0.00 -32.3%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 86 (top 14%)
✓Trading at only 0.5x book value

✗Weaknesses

✗Negative free cash flow
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM12.71%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM78.84%

EPS CAGR

10Y-

5Y-

3Y-

TTM80%

ROCE

10Y Avg-54.95%

5Y Avg-46.12%

3Y Avg-56.14%

Latest-71.92%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	636K
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	26.34K	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	-26.34K	0	0	0	0	636K
Gross Margin %	-	-	-	-	-	1%
Gross Profit Growth %	-	1%	-	-	-	-
Operating Expenses+	17.64M	25.3M	45.65M	67.88M	78.93M	61.13M
OpEx % of Revenue	-	-	-	-	-	96.12%
Selling, General & Admin	6.28M	7.67M	18.74M	27.2M	25.39M	19.63M
SG&A % of Revenue	-	-	-	-	-	30.86%
Research & Development	11.37M	17.63M	26.91M	40.69M	53.54M	41.51M
R&D % of Revenue	-	-	-	-	-	65.26%
Other Operating Expenses	0	0	0	0	0	0
Operating Income+	-17.64M	-25.3M	-45.65M	-67.88M	-78.93M	-60.5M
Operating Margin %	-	-	-	-	-	-95.12%
Operating Income Growth %	-	-0.43%	-0.8%	-0.49%	-0.16%	0.23%
EBITDA+	-17.62M	-25.24M	-45.54M	-67.72M	-78.78M	-60.37M
EBITDA Margin %	-	-	-	-	-	-94.91%
EBITDA Growth %	-	-0.43%	-0.8%	-0.49%	-0.16%	0.23%
D&A (Non-Cash Add-back)	26.34K	62K	109K	167K	150K	131K
EBIT	-17.42M	-25.3M	-45.5M	-67.88M	-78.93M	-60.5M
Net Interest Income+	158K	122K	44K	1.96M	6.15M	4.22M
Interest Income	197K	171K	54K	1.96M	6.15M	4.22M
Interest Expense	39K	49K	10K	0	0	0
Other Income/Expense	182K	-1.16M	-1.36M	155K	4.37M	2.72M
Pretax Income+	-17.46M	-26.46M	-47.01M	-67.73M	-74.56M	-57.77M
Pretax Margin %	-	-	-	-	-	-90.84%
Income Tax+	0	-15K	0	-1.07M	0	0
Effective Tax Rate %	1.01%	1%	1%	0.98%	1%	1%
Net Income+	-17.63M	-26.45M	-47.01M	-66.65M	-74.56M	-57.77M
Net Margin %	-	-	-	-	-	-90.84%
Net Income Growth %	-	-0.5%	-0.78%	-0.42%	-0.12%	0.23%
Net Income (Continuing)	-17.46M	-26.45M	-47.01M	-66.65M	-74.56M	-57.77M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.79	-1.19	-1.46	-2.09	-1.84	-1.33
EPS Growth %	-	-0.51%	-0.23%	-0.43%	0.12%	0.28%
EPS (Basic)	-0.55	-1.19	-1.46	-2.09	-1.84	-1.33
Diluted Shares Outstanding	22.24M	22.24M	32.13M	31.82M	40.45M	43.55M
Basic Shares Outstanding	22.24M	22.24M	32.13M	31.82M	40.45M	43.55M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	20.92M	141.26M	180.87M	179.5M	114.79M	67.84M
Cash & Short-Term Investments	19.46M	140.23M	175.33M	168.99M	109.93M	65.51M
Cash Only	19.46M	140.23M	175.33M	56.96M	24.49M	13.9M
Short-Term Investments	0	0	0	112.04M	85.44M	51.61M
Accounts Receivable	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	395K	1.05M	2.05M	995K
Total Non-Current Assets+	687K	597K	1.32M	939K	831K	267K
Property, Plant & Equipment	199K	287K	511K	909K	592K	267K
Fixed Asset Turnover	-	-	-	-	-	2.38x
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	488K	310K	805K	30K	239K	0
Other Non-Current Assets	0	0	0	0	0	0
Total Assets+	21.61M	141.86M	182.19M	180.44M	115.62M	68.11M
Asset Turnover	-	-	-	-	-	0.01x
Asset Growth %	-	5.57%	0.28%	-0.01%	-0.36%	-0.41%
Total Current Liabilities+	3.81M	5.84M	6.55M	10.74M	9.26M	6.24M
Accounts Payable	857K	1.58M	603K	1.11M	976K	278K
Days Payables Outstanding	11.87K	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	848K
Other Current Liabilities	1.59M	0	2.99M	4.7M	3.17M	3.1M
Current Ratio	5.50x	24.18x	27.61x	16.71x	12.39x	10.87x
Quick Ratio	5.50x	24.18x	27.61x	16.71x	12.39x	10.87x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	941K	12K	32K	374K	173K	212K
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	374K	173K	0
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	941K	12K	32K	0	0	0
Total Liabilities	4.75M	5.86M	6.58M	11.12M	9.44M	6.45M
Total Debt+	0	0	0	555K	392K	154K
Net Debt	-19.46M	-140.23M	-175.33M	-56.4M	-24.1M	-13.75M
Debt / Equity	-	-	-	0.00x	0.00x	0.00x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-452.36x	-516.39x	-4564.80x	-	-	-
Total Equity+	16.86M	136M	175.6M	169.32M	106.18M	61.65M
Equity Growth %	-	7.07%	0.29%	-0.04%	-0.37%	-0.42%
Book Value per Share	0.76	6.11	5.47	5.32	2.63	1.42
Total Shareholders' Equity	16.86M	136M	175.6M	169.32M	106.18M	61.65M
Common Stock	230K	2K	3K	4K	4K	4K
Retained Earnings	-20.57M	-47.01M	-94.03M	-160.68M	-235.25M	-293.02M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	56K	0	0	-214K	15K	68K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-15.03M	-22.04M	-45.53M	-57.28M	-60.27M	-49.28M
Operating CF Margin %	-	-	-	-	-	-77.49%
Operating CF Growth %	-	-0.47%	-1.07%	-0.26%	-0.05%	0.18%
Net Income	-17.56M	-26.45M	-47.01M	-66.65M	-74.56M	-57.77M
Depreciation & Amortization	26K	62K	109K	167K	150K	131K
Stock-Based Compensation	194K	704K	3.65M	9.5M	10.92M	7.99M
Deferred Taxes	103K	0	0	0	0	0
Other Non-Cash Items	144K	1.52M	1.5M	640K	-1.05M	627K
Working Capital Changes	2.07M	2.12M	-3.78M	-936K	4.28M	-258K
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	728K	723K	-976K	487K	-99K	-698K
Cash from Investing+	-188K	-2.07M	-2.33M	-112.17M	27.66M	33.49M
Capital Expenditures	-188K	-137K	-333K	-54K	-12K	0
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	-1.94K	-2K	0	2.25M	0
Cash from Financing+	31.57M	144.89M	82.97M	51.08M	143K	5.2M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	-33K	-319K	-3.23M	-455K	0	-206K
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-15.21M	-22.18M	-45.87M	-57.34M	-60.28M	-49.28M
FCF Margin %	-	-	-	-	-	-77.49%
FCF Growth %	-	-0.46%	-1.07%	-0.25%	-0.05%	0.18%
FCF per Share	-0.68	-1.00	-1.43	-1.80	-1.49	-1.13
FCF Conversion (FCF/Net Income)	0.85x	0.83x	0.97x	0.86x	0.81x	0.85x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-104.54%	-34.6%	-30.17%	-38.65%	-54.13%	-68.85%
Return on Invested Capital (ROIC)	-	-	-	-89.97%	-60.72%	-69.81%
Gross Margin	-	-	-	-	-	100%
Net Margin	-	-	-	-	-	-9084.12%
Debt / Equity	-	-	-	0.00x	0.00x	0.00x
Interest Coverage	-452.36x	-516.39x	-4564.80x	-	-	-
FCF Conversion	0.85x	0.83x	0.97x	0.86x	0.81x	0.85x

Revenue by Segment

	2024
Collaboration And License Revenue	636K
Collaboration And License Revenue Growth	-

Frequently Asked Questions

Growth & Financials

Rallybio Corporation (RLYB) reported $0.7M in revenue for fiscal year 2024.

Rallybio Corporation (RLYB) grew revenue by 0.0% over the past year. Growth has been modest.

Rallybio Corporation (RLYB) reported a net loss of $14.2M for fiscal year 2024.

Dividend & Returns

Rallybio Corporation (RLYB) has a return on equity (ROE) of -68.8%. Negative ROE indicates the company is unprofitable.

Rallybio Corporation (RLYB) had negative free cash flow of $35.0M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener